Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohortAndrea Serafin, Andrea Visentin, Monia Marchetti et al.|Blood Advances|2025Cited by 3
Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)Enrica Antonia Martino, Federico Vozzella, Raffaella Pasquale et al.|Blood|2024Cited by 0
Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.Luca Laurenti, Idanna Innocenti, Antonio Mosca et al.|Blood|2025Cited by 0